Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical Cancer

Bosch, 2002, The causal relation between human papillomavirus and cervical cancer, J Clin Pathol, 55, 244, 10.1136/jcp.55.4.244

Arbyn, 2006, Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses, Vaccine, 24, S78, 10.1016/j.vaccine.2006.05.117

Koliopoulos, 2007, Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non randomised studies, Gynecol Oncol, 104, 232, 10.1016/j.ygyno.2006.08.053

Meijer, 2009, Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older, Int J Cancer, 124, 516, 10.1002/ijc.24010

Arbyn, 2012, The APTIMA HPV assay versus the Hybrid Capture II test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy, Int J Cancer

Poljak, 2012, Nucleic acid tests for the detection of alpha human papillomaviruses, Vaccine, 30, F100, 10.1016/j.vaccine.2012.04.105

Davies, 2006, A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening, Int J Cancer, 118, 791, 10.1002/ijc.21611

Sankaranarayanan, 2005, A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India, Int J Cancer, 116, 617, 10.1002/ijc.21050

Ronco, 2006, Human Papillomavirus testing and liquid-based cytology in primary cervical screening: results at recruitment from the New Technologies for Cervical Cancer randomized controlled trial, J Natl Cancer Inst, 98, 765, 10.1093/jnci/djj209

Mayrand, 2007, Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer, N Engl J Med, 357, 1579, 10.1056/NEJMoa071430

Naucler, 2007, Human papillomavirus and Papanicolaou tests to screen for cervical cancer, N Engl J Med, 357, 1589, 10.1056/NEJMoa073204

Ronco, 2008, Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test, J Natl Cancer Inst, 100, 492, 10.1093/jnci/djn065

Leinonen, 2009, Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting, J Natl Cancer Inst, 101, 1612, 10.1093/jnci/djp367

Kitchener, 2009, HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial, Lancet Oncol, 10, 672, 10.1016/S1470-2045(09)70156-1

Arbyn, 2009, Trials comparing cytology with human papillomavirus screening, Lancet Oncol, 10, 935, 10.1016/S1470-2045(09)70296-7

Bulkmans, 2007, Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial, Lancet, 370, 796, 10.1016/S0140-6736(07)61450-0

Ronco, 2010, Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial, Lancet Oncol, 11, 249, 10.1016/S1470-2045(09)70360-2

Rijkaart, 2012, Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial, Lancet Oncol, 13, 78, 10.1016/S1470-2045(11)70296-0

Sankaranarayanan, 2009, HPV screening for cervical cancer in Rural India, N Engl J Med, 360, 1385, 10.1056/NEJMoa0808516

Rijkaart, 2012, Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening, Int J Cancer, 130, 602, 10.1002/ijc.26056

Dillner, 2008, Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study, BMJ, 337, a1754, 10.1136/bmj.a1754

Katki, 2011, Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice, Lancet Oncol, 12, 666, 10.1016/S1470-2045(11)70145-0

Sherman, 2003, Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: A 10-Year cohort analysis, J Natl Cancer Inst, 95, 46, 10.1093/jnci/95.1.46

Heideman, 2011, Clinical validation of the cobas(R)4800 HPV Test for cervical screening purposes, J Clin Microbiol, 49, 3983, 10.1128/JCM.05552-11

Hesselink, 2010, Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+/6+-PCR-enzyme immunoassay in population-based cervical screening, J Clin Microbiol, 48, 797, 10.1128/JCM.01743-09

Poljak, 2011, Comparison of clinical and analytical performance of the Abbott RealTime High Risk HPV test to the performance of Hybrid Capture 2 in population-based cervical cancer screening, J Clin Microbiol, 49, 1721, 10.1128/JCM.00012-11

Carozzi, 2011, Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of Hybrid Capture 2 assay in a screening setting, J Clin Microbiol, 49, 1446, 10.1128/JCM.02311-10

Cuzick, 2012, New technologies and procedures for cervical cancer screening, Vaccine, 30, F107, 10.1016/j.vaccine.2012.05.088

Arbyn, 2009, Triage of women with equivocal or low-grade cervical cytology results. A meta-analysis of the HPV test positivity rate, J Cell Mol Med, 13, 648, 10.1111/j.1582-4934.2008.00631.x

Arbyn, 2004, Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia, J Natl Cancer Inst, 96, 280, 10.1093/jnci/djh037

Roelens, 2012, p16INK4a immunocytochemistry versus HPV testing for triage of women with minor cytological abnormalities: A systematic review and meta-analysis, Cancer

Jordan, 2008, European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1, Cytopathology, 19, 342, 10.1111/j.1365-2303.2008.00623.x

Wright, 2007, 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests, Am J Obstet Gynecol, 197, 346, 10.1016/j.ajog.2007.07.047

Bais, 2005, Triage using HPV-testing in persistent borderline and mildly dyskaryotic smears: Proposal for new guidelines, Int J Cancer, 116, 122, 10.1002/ijc.20958

Moscicki, 2004, Regression of low-grade squamous intra-epithelial lesions in young women, Lancet, 364, 1678, 10.1016/S0140-6736(04)17354-6

Solomon, 2009, Clin Pathol, 131, 768, 10.1309/AJCPQCIBCZ22ZIMG

Flannelly, 2001, Follow up after LLETZ: could schedules be modified according to risk of recurrence?, BJOG, 108, 1025

Castle, 2005, A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis, 191, 1808, 10.1086/428779

Soutter, 2005, Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia, Int J Cancer, 118, 2048, 10.1002/ijc.21604

Kocken, 2011, Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study, Lancet Oncol, 12, 441, 10.1016/S1470-2045(11)70078-X

Cuzick, 2008, Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries, Vaccine, 26, K29, 10.1016/j.vaccine.2008.06.019

European Commission, 2008

Rijkaart, 2010, Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test, Br J Cancer, 103, 839, 10.1038/sj.bjc.6605869

Saslow, 2012, American Cancer Society American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer, CA Cancer J Clin, 10.3322/caac.21139

Naucler, 2009, Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening, J Natl Cancer Inst, 101, 88, 10.1093/jnci/djn444

Castle, 2009, Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study, BMJ, 339, b2569, 10.1136/bmj.b2569

Khan, 2005, The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice, J Natl Cancer Inst, 97, 1072, 10.1093/jnci/dji187

Castle, 2011, Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study, Lancet Oncol, 12, 880, 10.1016/S1470-2045(11)70188-7

Monsonego, 2011, Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid based cytology in primary cervical cancer screening (The FASE study), Int J Cancer, 129, 691, 10.1002/ijc.25726

Rebolj, 2011, Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review, BMJ, 342, d2757, 10.1136/bmj.d2757

Kulmala, 2004, Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools, J Clin Microbiol, 42, 2470, 10.1128/JCM.42.6.2470-2475.2004

Qiao, 2008, A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China, Lancet Oncol, 9, 929, 10.1016/S1470-2045(08)70210-9

Wu, 2010, Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I, Int J Gynecol Cancer, 20, 1411

Belinson, 2011, A population-based clinical trial comparing endocervical high-risk HPV testing using hybrid capture 2 and Cervista from the SHENCCAST II Study, Am J Clin Pathol, 135, 790, 10.1309/AJCPKA6ATAPBZ6JQ

Belinson, 2012, Improved sensitivity of vaginal self-collection and high-risk human papillomavirus testing, Int J Cancer, 130, 1855, 10.1002/ijc.26202